Evelo Biosciences, Inc. (39)

Browse by Contract Category

Contracts

Loan and Security Agreement by and among Evelo Biosciences, Inc. and Horizon Technology Finance Corporation, dated December 15, 2022 (Filed With SEC on December 16, 2022)
Offer Letter, dated (Filed With SEC on November 14, 2022)
Sales Agreement, dated July 1, 2022, between Evelo Biosciences, Inc. and Cowen and Company, LLC (Filed With SEC on July 1, 2022)
Patent License Agreement between Mayo Foundation for Medical Education and Research and Evelo Biosciences, Inc., dated August 6, 2017, as amended January 19, 2018 and further... (Filed With SEC on March 24, 2022)
Evelo Biosciences, Inc. Non-Employee Director Compensation Program, as amended, effective April 1, 2022 (Filed With SEC on March 24, 2022)
Form of Warrant to Purchase Common Stock, dated as of December 15, 2022, issued by Evelo Biosciences, Inc. to Horizon Technology Finance Corporation, together with a schedule of... (Filed With SEC on December 16, 2022)
Modification Letter (Filed With SEC on November 14, 2022)
Amended and Restated Warrant to Purchase Common Stock, dated as of (Filed With SEC on November 14, 2022)
Offer Letter (Filed With SEC on August 11, 2022)
Offer Letter (Filed With SEC on August 11, 2022)
Form of Securities Purchase Agreement, dated May 25, 2022, by and among the Company and the several Purchasers named therein (Filed With SEC on May 25, 2022)
Amendment No. 1 to Clinical Master Services Agreement between Evelo Biosciences, Inc. and Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany, dated February 8, 2022 (Filed With SEC on March 24, 2022)
Employment Agreement of Mark Bodmer by and between Evelo Biosciences (UK) Limited and Mark Bodmer, dated December 31, 2021 (Filed With SEC on January 4, 2022)
Evelo Biosciences, Inc. Non-Employee Director Compensation Program, as amended June 9, 2021 (Filed With SEC on July 29, 2021)
Fourth Amendment, dated of June 16, 2021, to the (Filed With SEC on June 17, 2021)
Warrant to Purchase Common Stock, dated as of June 16, 2021, issued by Evelo Biosciences, Inc. to K2 HealthVentures Equity Trust LLC (Filed With SEC on June 17, 2021)
Amendment dated April 9, 2021 to Letter Agreement between Evelo Biosciences, Inc. and David R. Epstein (Filed With SEC on April 29, 2021)
Amendment No. 2 to Consulting Agreement dated April 9, 2021 between Evelo Biosciences, Inc. and David R. Epstein (Filed With SEC on April 29, 2021)
Commercialization and License Agreement dated March 17, 2021 by and among Evelo Biosciences, Inc. and Meddist Company Limited (Filed With SEC on March 23, 2021)
Development and Clinical Master Services Agreement between Evelo Biosciences, Inc. and Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany dated December 17, 2020 (Filed With SEC on March 9, 2021)
Underwriting Agreement, dated January 28, 2021, by and among the Company and Morgan Stanley & Co. LLC and Cowen and Company, LLC, as representatives of the several underwriters... (Filed With SEC on February 2, 2021)
Consulting Agreement, dated September 16, 2019, between Evelo Biosciences, Inc. and David R. Epstein, as amended (Filed With SEC on October 30, 2020)
Letter Agreement, dated September 16, 2019, between Evelo Biosciences, Inc. and David R. Epstein, as amended (Filed With SEC on October 30, 2020)
Third Amendment to Loan and Security Agreement dated as of July 8, 2020 by and among Evelo Biosciences, Inc., the lenders party thereto and K2 HealthVentures LLC, as... (Filed With SEC on July 31, 2020)
Second Amendment to Loan and Security Agreement dated as of May 15, 2020 by and among Evelo Biosciences, Inc., the lenders party thereto and K2 HealthVentures LLC, as... (Filed With SEC on May 18, 2020)
2018 Employee Stock Purchase Plan, as amended (Filed With SEC on February 14, 2020)
Description of Capital Stock (Filed With SEC on February 14, 2020)
Executive Severance Plan, as amended (Filed With SEC on February 14, 2020)
Non-Employee Director Compensation Program, as amended (Filed With SEC on February 14, 2020)
Amendment No. 1 to Exclusivity and Commitment Agreement between Evelo Biosciences, Inc. and Biose Industrie, dated as of August 1, 2019 (Filed With SEC on November 5, 2019)
Letter Agreement, dated September 16, 2019, between Evelo Biosciences, Inc. and David R. Epstein (Filed With SEC on September 18, 2019)
Consulting Agreement, dated September 16, 2019, between Evelo Biosciences, Inc. and David R. Epstein (Filed With SEC on September 18, 2019)
Loan and Security Agreement between Pacific Western Bank and Evelo Biosciences, Inc., dated August 15, 2016, as amended on June 14, 2017, August 18, 2017, February 7, 2018, March... (Filed With SEC on August 6, 2019)
Collaboration Agreement between Evelo Biosciences, Inc. and Sacco S.r.l., dated July 9, 2019 (Filed With SEC on August 6, 2019)
Loan and Security Agreement by and among Evelo Biosciences, Inc. and the other borrowers party thereto, the lenders party thereto, K2 HealthVentures LLC, as administrative agent... (Filed With SEC on August 6, 2019)
Loan and Security Agreement by and among Evelo Biosciences, Inc. and the other borrowers party thereto, the lenders party thereto, K2 HealthVentures LLC, as administrative agent... (Filed With SEC on July 24, 2019)
Loan and Security Agreement between Pacific Western Bank and Evelo Biosciences, Inc., dated August 15, 2016, as amended on June 14, 2017, August 18, 2017, February 7, 2018, March... (Filed With SEC on May 3, 2019)
Terms and Conditions of Employment between Evelo Biosciences (UK) Limited and Duncan McHale, M.B.B.S., Ph.D., effective May 1, 2019 (Filed With SEC on April 25, 2019)
Master Services Agreement, dated September 1, 2018, between Evelo Biosciences, Inc. and Weatherden Ltd (Filed With SEC on February 15, 2019)